Market Overview

The global Microneedle Drug Delivery Systems Market is anticipated to experience significant growth, expanding from USD 2.59 billion in 2022 to USD 3.82 billion by 2029, at a CAGR of 5.5% during the forecast period of 2023-2029. Microneedle drug delivery systems offer a non-invasive and painless approach to administering drugs and vaccines. These systems utilize tiny needles to create micro-pores on the skin, enabling efficient and targeted drug delivery. The market was notably impacted by the COVID-19 pandemic, which prompted the development of innovative skin patches for drug delivery purposes. Companies operating in the market are actively focusing on the advancement of microneedle patches and drug delivery systems.

The increasing prevalence of chronic diseases, such as diabetes and cardiovascular disorders, has created a pressing need for efficient and convenient drug delivery methods. Microneedle systems offer a safer and more patient-friendly alternative to traditional injections, contributing to their rising adoption.

Furthermore, advancements in painless drug delivery research and technological progress have significantly enhanced the efficacy and usability of microneedle drug delivery systems. These advancements have garnered attention from both healthcare professionals and patients, further propelling market growth.

The growing diabetic population and the rise in chronic diseases worldwide have also fueled the demand for microneedle drug delivery systems. These systems provide a convenient and efficient means of administering medications, particularly for individuals who require frequent injections.

Moreover, ongoing research studies on microneedles and the introduction of new product launches have further stimulated market growth. Market players are actively investing in research and development activities to expand the application areas of microneedle drug delivery systems and improve their performance.

However, the market does face certain limitations that may impede its growth. The availability of approved products in the market is relatively limited, posing challenges for widespread adoption. Additionally, potential complications associated with microneedles, such as skin irritation or infection, need to be carefully addressed to ensure patient safety and confidence.

Market Segmentation

The market is segmented based on product type, application, and geography.

Segmentation by Product Type
Solid
Hollow
Coated
Dissolvable

Segmentation by Application
Drug Delivery
Vaccine Delivery
Dermatology
Others

Segmentation by Geography
North America – United States, Canada, and Mexico
Europe – United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific – China, Japan, South Korea, India, Australia, and Rest of Asia-Pacific
Rest of the World

The microneedle drug delivery market is expected to grow in vaccine delivery due to the increasing prevalence of influenza and viral infections. Microneedle vaccinations have shown effectiveness in generating a strong immune response by delivering vaccines efficiently to immune cell-rich skin regions. The use of sustained-release polymers or integrated microparticles and nanoparticles in microneedles can eliminate the need for multiple vaccinations, increasing demand for such vaccine delivery systems. Additionally, company focus on business strategies like mergers and collaborations, along with more vaccine launches, will contribute to the growth of the vaccine delivery segment.

The North American market for microneedle drug delivery systems is expected to grow due to the rising prevalence of chronic, skin, and infectious diseases. Technological advancements in microneedle fabrication further promote adoption. The region’s burden of chronic diseases and high flu cases drive demand for microneedle drug delivery. Strategic initiatives like collaborations contribute to market growth. In conclusion, the microneedle drug delivery market, especially for vaccines, will see significant growth due to infectious diseases, technological advancements, and strategic initiatives.

Competitive Landscape

The market for microneedle drug delivery systems is fragmented and highly competitive, with a few major players holding dominant market share. Key companies in this market include Becton, Dickinson and Company, Candela Corporation, Corium Inc., CosMED Pharmaceutical Co., Ltd., Debiotech S.A., LTS Lohmann Therapie-Systeme AG, Micropoint Technologies Pte Ltd, nanoBioSciences, LLC (DBA AdminMed), NanoPass Technologies Ltd., Raphas Co., Ltd., among others.

Recent Industry Developments

In October 2022, Emergex Vaccines Holding Limited successfully acquired Zosano Pharma Corporation’s assets. These assets include valuable intellectual property, license agreements, manufacturing equipment, and Zosano’s proprietary microneedle array patch (MAP) intradermal drug delivery system. The acquisition also included rights to solid-coated microneedle array patch technology, formulation and coating methods, and specialized equipment.

CGBio, a South Korean healthcare provider, launched CGDew Derma Regen, a new skin care patch in November 2022. The patch is part of their microneedle pipeline and is made from various materials such as silicon, titanium, stainless steel, and polymers. It aims to improve medication diffusion by creating tiny pores on the skin.

Why Choose This Report

Gain a reliable outlook of the global microneedle drug delivery systems market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.